This company has been acquired
Crinetics Pharmaceuticals Gestione
Criteri Gestione verificati 2/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
R. Struthers
Amministratore delegato
US$11.6m
Compenso totale
| Percentuale dello stipendio del CEO | 6.18% |
| Mandato del CEO | 17.8yrs |
| Proprietà del CEO | n/a |
| Durata media del management | 3.4yrs |
| Durata media del Consiglio di amministrazione | 6yrs |
Aggiornamenti recenti sulla gestione
Recent updates
CRNX: Vertex Deal Price Will Anchor Shares As Endocrine Data Progresses
Crinetics Pharmaceuticals' analyst price target has reset toward the agreed $85 per share cash acquisition price, with updated models reflecting the $85.50 fair value estimate and the view from multiple firms that the Vertex deal now anchors both the upside and downside scenarios. Analyst Commentary Recent research on Crinetics Pharmaceuticals points to a clear shift in focus toward the US$85 per share cash offer from Vertex Pharmaceuticals as the key reference point for valuation.
CRNX: Takeover Offer And Delayed Rival Entry Will Shape Endocrine Outlook
Crinetics Pharmaceuticals' analyst fair value estimate has been trimmed from $97 to $90 as analysts recalibrate expectations around the $85 per share cash acquisition by Vertex Pharmaceuticals and the cluster of rating downgrades to Hold or Neutral that now anchor views closer to the agreed deal price. Analyst Commentary Analysts covering Crinetics Pharmaceuticals are now largely treating the stock as a merger arbitrage situation, with ratings concentrated around Hold or Neutral and price targets aligning closely with the agreed US$85 per share cash offer from Vertex Pharmaceuticals.Vertex To Acquire Crinetics For ~$10bn - What Investors Should Know
Summary Vertex Pharmaceuticals Incorporated acquires Crinetics Pharmaceuticals, Inc. for $85/share, valuing the deal at ~$10bn to diversify beyond its cystic fibrosis franchise. CRNX brings PALSONIFY, a newly approved oral acromegaly therapy with blockbuster potential, and atumelnant, a Phase 3 CAH candidate, strengthening VRTX's rare disease portfolio. VRTX expects Crinetics' assets to deliver up to $5bn peak annual revenues, supporting a path toward five blockbuster products and ~$20bn revenues by 2030. The CRNX acquisition is funded by cash and debt, leveraging VRTX's strong balance sheet, with anticipated deal closure in Q3 2026 and minimal near-term financial strain. Read the full article on Seeking AlphaCRNX: Delayed Rival Entry Will Support Early Acromegaly Launch Execution
The analyst fair value estimate for Crinetics Pharmaceuticals has been revised from $108.00 to $97.00, with analysts citing a reset to more moderate revenue growth, a slightly higher discount rate, and updated assumptions around future margins and P/E multiples, even as they highlight potential benefits from delayed competitive pressure in acromegaly following the Oclaiz complete response letter. Analyst Commentary Recent research coverage on Crinetics Pharmaceuticals highlights a mix of valuation resets and constructive views on the launch setup for Palsonify in acromegaly.Crinetics Pharmaceuticals (CRNX) Stock Could Be 56.5% Undervalued After ENDO 2026 Data
Crinetics Pharmaceuticals (CRNX) is back in focus after presenting extensive new data at the Endocrine Society’s 2026 meeting, covering both its approved acromegaly drug PALSONIFY and its investigational ACTH receptor antagonist atumelnant. See our latest analysis for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals’ recent ENDO 2026 updates have arrived alongside a mixed share price picture, with a 7 day share price return of 6.98% contrasting with a year to date decline of 23.24%, while...Industry Analysts Just Upgraded Their Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Revenue Forecasts By 11%
Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX ) shareholders will have a reason to smile today, with the analysts...Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness
Summary Crinetics Pharmaceuticals is currently overvalued but holds strong Wall Street support with a $75.07 average price target, indicating a 47.43% upside. The FDA accepted Crinetics' NDA for paltusotine, setting a PDUFA date of 09/24/2025. Crinetics is preparing for a fall 2025 launch of paltusotine, engaging with payers and endocrinologists to ensure broad patient access and formulary placement. Despite its valuation, Crinetics' advancements in acromegaly treatment and strong Wall Street backing make it a hold and potential acquisition on pullbacks. Read the full article on Seeking AlphaCrinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech
Summary Paltusotine in the treatment of acromegaly is Crinetics lead therapy with NDA filing planned in H2 2024. Crinetics has no approved drug and its lead therapy will face significant competition once approved. Investors should be aware of the high-risk nature of investing in Crinetics Pharmaceuticals. Read the full article on Seeking AlphaAnalisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$502m |
| Mar 31 2026 | n/a | n/a | -US$496m |
| Dec 31 2025 | US$12m | US$719k | -US$465m |
| Sep 30 2025 | n/a | n/a | -US$423m |
| Jun 30 2025 | n/a | n/a | -US$370m |
| Mar 31 2025 | n/a | n/a | -US$328m |
| Dec 31 2024 | US$11m | US$654k | -US$298m |
| Sep 30 2024 | n/a | n/a | -US$278m |
| Jun 30 2024 | n/a | n/a | -US$259m |
| Mar 31 2024 | n/a | n/a | -US$235m |
| Dec 31 2023 | US$6m | US$614k | -US$215m |
| Sep 30 2023 | n/a | n/a | -US$199m |
| Jun 30 2023 | n/a | n/a | -US$184m |
| Mar 31 2023 | n/a | n/a | -US$175m |
| Dec 31 2022 | US$6m | US$590k | -US$164m |
| Sep 30 2022 | n/a | n/a | -US$150m |
| Jun 30 2022 | n/a | n/a | -US$136m |
| Mar 31 2022 | n/a | n/a | -US$119m |
| Dec 31 2021 | US$4m | US$567k | -US$108m |
| Sep 30 2021 | n/a | n/a | -US$98m |
| Jun 30 2021 | n/a | n/a | -US$89m |
| Mar 31 2021 | n/a | n/a | -US$79m |
| Dec 31 2020 | US$4m | US$544k | -US$74m |
| Sep 30 2020 | n/a | n/a | -US$67m |
| Jun 30 2020 | n/a | n/a | -US$63m |
| Mar 31 2020 | n/a | n/a | -US$59m |
| Dec 31 2019 | US$4m | US$542k | -US$50m |
Compensazione vs Mercato: La retribuzione totale di R. ($USD 11.63M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 8.44M ).
Compensazione vs guadagni: La retribuzione di R. è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
R. Struthers (64 yo)
Dr. R. Scott Struthers, Ph.D. founded Crinetics Pharmaceuticals, Inc. in November 2008 and serves as its Chief Executive Officer and President since December 2008. He is Chairman at Radionetics Oncology, I...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | no data | Nessun dato | Nessun dato | |
| Founder | 17.8yrs | US$11.63m | Nessun dato | |
| Co-Founder & Chief Scientific Officer | 18.7yrs | US$3.83m | 0% $ 0 | |
| Secretary | no data | Nessun dato | Nessun dato | |
| Chief Financial Officer | 1.6yrs | US$4.45m | 0% $ 0 | |
| Treasurer | no data | Nessun dato | Nessun dato | |
| Chief Information Officer | 1.5yrs | Nessun dato | Nessun dato | |
| Head of Investor Relations | no data | Nessun dato | Nessun dato | |
| Chief Legal Officer & Corporate Secretary | 5.3yrs | Nessun dato | Nessun dato | |
| Head of Corporate Communications | no data | Nessun dato | Nessun dato | |
| Chief Human Resources Officer | 6.3yrs | Nessun dato | Nessun dato | |
| Chief Endocrinologist | 8.3yrs | US$2.16m | Nessun dato | |
| Head of Intellectual Property | no data | Nessun dato | Nessun dato | |
| Chief Business Officer | 4.5yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Medical Affairs | 2.3yrs | Nessun dato | Nessun dato |
Gestione esperta: Il team dirigenziale di CRNX è considerato esperto (durata media dell'incarico 3.4 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder | 17.8yrs | US$11.63m | Nessun dato | |
| Independent Chairman of the Board | 10.9yrs | US$528.62k | 0% $ 0 | |
| Independent Director | 8.6yrs | US$498.59k | 0% $ 0 | |
| Independent Director | 6yrs | US$500.47k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 4.7yrs | US$507.34k | 0% $ 0 | |
| Independent Director | 8.6yrs | US$493.84k | 0% $ 0 | |
| Independent Director | 7.2yrs | US$500.47k | 0% $ 0 | |
| Independent Director | 4.5yrs | US$485.47k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.4yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 4.4yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 4.4yrs | Nessun dato | Nessun dato |
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CRNX sono considerati esperti (durata media dell'incarico 6 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/03 05:21 |
| Prezzo dell'azione a fine giornata | 2026/08/31 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Crinetics Pharmaceuticals, Inc. è coperta da 19 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Brian Skorney | Baird |
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| David Lebowitz | Citigroup Inc |